1-20 of 23
David F. McDermott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura Fernandes, Chana Weinstock, Michael B. Atkins, Sundeep Agrawal, Rajeshwari Sridhara, Nicole Gormley, Shenghui Tang, Daniel L. Suzman, Laleh Amiri-Kordestani, Paul G. Kluetz, Richard Pazdur, Brian I. Rini, David F. McDermott, Meredith M. Regan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3282–3286.
https://doi.org/10.1158/1078-0432.CCR-23-3719
Published: 01 August 2024
View article titled, A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Open the PDF for A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Thomas Denize, Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton, Aseman Sheshdeh Bagheri, Varunika Savla, Yasmin Nabil Laimon, Saurabh Gupta, Sai Vikram Vemula, David A. Braun, Kelly P. Burke, Paul J. Catalano, Gordon J. Freeman, Robert J. Motzer, Michael B. Atkins, David F. McDermott, Arlene H. Sharpe, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 803–813.
https://doi.org/10.1158/1078-0432.CCR-23-2274
Published: 16 February 2024
View article titled, PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Open the PDF for PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

Miriam Ficial, Opeyemi A. Jegede, Miriam Sant'Angelo, Yue Hou, Abdallah Flaifel, Jean-Christophe Pignon, David A. Braun, Megan Wind-Rotolo, Maura A. Sticco-Ivins, Paul J. Catalano, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sachet A. Shukla, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1371–1380.
https://doi.org/10.1158/1078-0432.CCR-20-3084
Published: 01 March 2021
View article titled, Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Open the PDF for Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jeronimo R. Rodriguez-Cid, Sumanta K. Pal, Andre M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 78–86.
https://doi.org/10.1158/1078-0432.CCR-20-2063
Published: 04 January 2021
View article titled, Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Open the PDF for Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5598–5608.
https://doi.org/10.1158/1078-0432.CCR-20-1408
Published: 02 November 2020
View article titled, Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Open the PDF for Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Michael B. Atkins, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, Carsten Grüllich, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piault-Louis, Christina Schiff, Bernard Escudier
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2506–2514.
https://doi.org/10.1158/1078-0432.CCR-19-2838
Published: 01 June 2020
View article titled, Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Open the PDF for Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz-Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O'Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6061–6072.
https://doi.org/10.1158/1078-0432.CCR-18-3488
Published: 15 October 2019
View article titled, Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Open the PDF for Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab in another window
Includes: Supplementary data
Journal Articles

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

Wenxin Xu, Maneka Puligandla, Judith Manola, Andrea J. Bullock, Daniel Tamasauskas, David F. McDermott, Michael B. Atkins, Naomi B. Haas, Keith Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Rupal S. Bhatt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6098–6106.
https://doi.org/10.1158/1078-0432.CCR-19-0818
Published: 15 October 2019
View article titled, Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Open the PDF for Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Jean-Christophe Pignon, Opeyemi Jegede, Sachet A. Shukla, David A. Braun, Christine E. Horak, Megan Wind-Rotolo, Yuko Ishii, Paul J. Catalano, Jonian Grosha, Abdallah Flaifel, Jesse S. Novak, Kathleen M. Mahoney, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Toni K. Choueiri, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2174–2184.
https://doi.org/10.1158/1078-0432.CCR-18-3206
Published: 01 April 2019
View article titled, irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Open the PDF for irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View article titled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma

Amy K. Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, James W. Mier, David J. Panka, David F. McDermott, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (9): 2159–2168.
https://doi.org/10.1158/1078-0432.CCR-16-1874
Published: 30 April 2017
View article titled, FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Open the PDF for FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5461–5471.
https://doi.org/10.1158/1078-0432.CCR-15-2839
Published: 14 November 2016
View article titled, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Open the PDF for Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albiges, Neeraj Agarwal, Thai H. Ho, Jiaxi Song, Jean-Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2445–2452.
https://doi.org/10.1158/1078-0432.CCR-15-2631
Published: 12 May 2016
View article titled, Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

David F. McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A. Margolin, Joseph I. Clark, Jeffrey A. Sosman, Janice P. Dutcher, Theodore F. Logan, Brendan D. Curti, Marc S. Ernstoff, Leonard Appleman, Michael K.K. Wong, Nikhil I. Khushalani, Leslie Oleksowicz, Ulka N. Vaishampayan, James W. Mier, David J. Panka, Rupal S. Bhatt, Alexandra S. Bailey, Bradley C. Leibovich, Eugene D. Kwon, Fairooz F. Kabbinavar, Arie S. Belldegrun, Robert A. Figlin, Allan J. Pantuck, Meredith M. Regan, Michael B. Atkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 561–568.
https://doi.org/10.1158/1078-0432.CCR-14-1520
Published: 01 February 2015
View article titled, The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma in another window
Journal Articles

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott, Amy Kramer, Lydia Giles, Kristi Gramlich, Mary Carberry, Andrea B. Troxel, Richard Letrero, Katherine L. Nathanson, Michael B. Atkins, Peter J. O'Dwyer, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7711–7718.
https://doi.org/10.1158/1078-0432.CCR-09-2074
Published: 14 December 2009
View article titled, Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Open the PDF for Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases in another window
Journal Articles

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Diana C. Gallagher, Rupal S. Bhatt, Samir M. Parikh, Parin Patel, Virginia Seery, David F. McDermott, Michael B. Atkins, Vikas P. Sukhatme
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2115–2120.
https://doi.org/10.1158/1078-0432.CCR-06-2509
Published: 02 April 2007
View article titled, Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak
Open the PDF for Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak in another window
Journal Articles

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Michael B. Atkins, Marc S. Ernstoff, Robert A. Figlin, Keith T. Flaherty, Daniel J. George, William G. Kaelin, Jr., Eugene D. Kwon, Towia A. Libermann, W. Marston Linehan, David F. McDermott, Augusto C. Ochoa, Allan J. Pantuck, Brian I. Rini, Mark A. Rosen, Jeffrey A. Sosman, Vikas P. Sukhatme, Johannes W. Vieweg, Christopher G. Wood, Laura King
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 667s–670s.
https://doi.org/10.1158/1078-0432.CCR-06-2231
Published: 25 January 2007
View article titled, Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
Open the PDF for Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference in another window
Journal Articles

Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma

David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 716s–720s.
https://doi.org/10.1158/1078-0432.CCR-06-1872
Published: 25 January 2007
View article titled, Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
Open the PDF for Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma in another window